Use of Metformin in Obese Women with Type i Endometrial Cancer Is Associated with a Reduced Incidence of Cancer Recurrence

International Journal of Gynecological Cancer

Volumn 26, Issue 2, 2016, Pages 313-317

  Hall, Christopher ^a   Stone, Rebecca L ^b   Gehlot, Ashita ^a   Zorn, Kristin K ^a   Burnett, Alexander F ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Endometrial cancer; Metformin; Obesity

Indexed keywords

ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; INSULIN; METFORMIN; ORAL ANTIDIABETIC AGENT; PROGESTERONE; ANTIDIABETIC AGENT;

ADULT; AGED; ARTICLE; BODY MASS; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; DEMOGRAPHY; DISEASE FREE SURVIVAL; ENDOMETRIUM CANCER; FEMALE; FOLLOW UP; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HUMAN; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRIORITY JOURNAL; ARKANSAS; COMPLICATION; ENDOMETRIAL NEOPLASMS; INCIDENCE; MIDDLE AGED; PREVENTION AND CONTROL; RETROSPECTIVE STUDY; TUMOR RECURRENCE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ARKANSAS; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INCIDENCE; METFORMIN; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OBESITY; RETROSPECTIVE STUDIES;

EID: 84957603034     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0000000000000603     Document Type: Article

References (37)

1. Park SL, Goodman MT, Zhang ZF, Body size, adult BMI gain and endometrial cancer risk: the multiethnic cohort. Int J Cancer. 2010; 126: 490-499.
2. Fader AN, Arriba LN, Frasure HE, Endometrial cancer and obesity: epidemiology, biomarkers, prevention and survivorship. Gynecol Oncol. 2009; 114: 121-127.
3. McCampbell AS, Broaddus RR, Loose DS, Overexpression of the insulin-like growth factor I receptor and activation of the AKT pathway in hyperplastic endometrium. Clin Cancer Res. 2006; 12: 6373-6378.
4. Gunter MJ, Hoover DR, Yu H, A prospective evaluation of insulin and insulin-like growth factor-I as risk factors for endometrial cancer. Cancer Epidemiol Biomarkers Prev. 2008; 17: 921-929.
5. Dowling RJ, Goodwin PJ, Stambolic V,. Understanding the benefit of metformin use in cancer treatment. BMC Med. 2011; 9: 33-39.
6. Ruiter R, Visser LE, van Herk-Sukel MP, Lower risk of cancer in patients on metformin in comparison with those on sulfonylurea derivatives: results from a large population-based follow-up study. Diabetes Care. 2012; 35: 119-124.
7. Libby G, Donnelly LA, Donnan PT, New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care. 2009; 32: 1620-1625.
8. Goodwin PJ, Pritchard KI, Ennis M, Insulin-lowering effects of metformin in women with early breast cancer. Clin Breast Cancer. 2008; 8: 501-505.
9. Dowling RJO, Zakakhani M, Fantus IG, Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Res. 2007; 67: 10804-10812.
10. Ogden CL, Carroll MD, Kit BK, Prevalence of obesity in the United States, 2009-2010. NCHS Data Brief. 2012; 1-8.
11. Lahmann PH, Hoffman K, Allen N, Body size and breast cancer risk: findings from the European prospective investigation into cancer and nutrition (EPIC). Int J Cancer. 2004; 111: 762-771.
12. Merry AHH, Schouten LJ, Goldbohm RA, Body mass index, height and risk of adenocarcinoma of the oesophagus and gastric cardia: a prospective cohort study. Gut. 2007; 56: 1503-1511.
13. Moghaddam AA, Woodward M, Huxley R,. Obesity and risk of colorectal cancer: a meta-analysis of 31 studies with 70,000 events. Cancer Epidemiol Biomarkers Prev. 2007; 16: 2533-2547.
14. Stewart ST, Cutler DM, Rosen AB,. Forecasting the effects of obesity and smoking on US life expectancy. N Engl J Med. 2009; 361: 2252-2260.
15. Renehan AG, Frystyk J, Flyvbjerg A,. Obesity and cancer risk: the role of the insulin-IGF axis. Trends Endocrinol Metab. 2006; 17: 328-336.
16. Paz-Filho G, Lim EL, Wong ML, Associations between adipokines and obesity-related cancer. Front Biosci. 2011; 16: 1634-1650.
17. Garofalo C, Surmacz E,. Leptin and cancer. J Cell Physiol. 2006; 207: 12-22.
18. Wozniak S, Gee L, Mitchell W, Adipose tissue: the new endocrine organ? A review article. Dig Dis Sci. 2009; 54: 1847-1856.
19. Ye J, Jia J, Dong S, Circulating adiponectin levels and the risk of breast cancer: a meta-analysis. Eur J Cancer Prev. 2014; 23: 158-165.
20. Kahn BB, Flier JS,. Obesity and insulin resistance. J Clin Invest. 2000; 106: 473-481.
21. Mu N, Zhu Y, Wang Y, Insulin resistance: A significant risk factor of endometrial cancer. Gynecol Oncol. 2012; 125: 751-757.
22. Wang C-F, Zhang G, Zhao L-J, Overexpression of the insulin receptor isoform a promotes endometrial carcinoma cell growth. PLoS One. 2013; 8: e69001.
23. Daka B, Rosen T, Jansson PA, Inverse association between serum insulin and sex hormone-binding globulin in a population survey in Sweden. Endocr Connect. 2013; 2: 18-22.
24. GLUCOPHAGE (metformin hydrochloride) Tablets GLUCOPHAGE XR (metformin hydrochloride) Extended-Release Tablets. Rx only. Distributed by Bristol-Myers Squibb Company, Princeton, NJ 08543 USA. Rev January. 2009, F5-B0001-01-09.
25. Feig DS, Moses RG,. Metformin therapy during pregnancy: good for the goose and good for the gosling too? Diabetes Care. 2011; 34: 2329-2330.
26. Lord JM, Flight IH, Norman RJ,. Metformin in polycystic ovary syndrome: systematic review and meta-analysis. BMJ. 2003; 327: 1-6.
27. The Diabetes Prevention Program Research Group. The 10-year cost-effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent-to-treat analysis of the DPP/DPPOS. Diabetes Care. 2012; 35: 723-730.
28. Bowker SL, Majumdar SR, Veugelers P, Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin: response to Farooki and Schneider. Diabetes Care. 2006; 2: 254-258.
29. Evans JM, Donnelly LA, Emslie-Smith AM, Metformin and reduced risk of cancer in diabetic patients. BMJ. 2005; 330: 1304-1305.
30. Kumar S, Meuter A, Thapa P, Metformin intake is associated with better survival in ovarian cancer: a case-control study. Cancer. 2013; 119: 555-562.
31. Landman GW, Kleefstra N, Hateren KJ, Metformin associated with lower cancer mortality in type 2 diabetes: ZODIAC-16. Diabetes Care. 2010; 33: 322-326.
32. Del Barco S, Vazquez-Martin A, Cufí S, Metformin: multi-faceted protection against cancer. Oncotarget. 2011; 2: 896-917.
33. De Leo V, La Marca A, Orvieto R, Effect of metformin on insulin-like growth factor (IGF) I and IGF-binding protein I in polycystic ovary syndrome. J Clin Endocrinol Metab. 2000; 85: 1598-1600.
34. Bruchim I, Sarfstein R, Werner H,. The IGF hormonal network in endometrial cancer: functions, regulation, and targeting approaches. Front Endocrinol. 2014; 5: 1-10.
35. Rice S, Pellatt L, Ramanathan K, Metformin inhibits aromatase via an ERK (extracellular signal-regulated kinase)-mediated pathway. Endocrinology. 2009; 150: 4794-4801.
36. Zhang Z, Dong L, Sui L, Metformin reverses progestin resistance in endometrial cancer cells by downregulating GloI expression. Int J Gynecol Cancer. 2011; 21: 213-221.
37. Tan BK, Adya R, Chen J, Metformin treatment exerts antiinvasive and antimetastatic effects in human endometrial carcinoma cells. J Clin Endocrinol Metab. 2011; 96: 808-816.